Free Newsletter
NICE looks askance at UCB's Cimzia
Free newsletter via e-mail
Tools
U.K. cost-effectiveness watchdog NICE says it's "minded not to recommended" the UCB drug Cimzia as a treatment option for rheumatoid arthritis, citing uncertainty embedded in economic models submitted by the company. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: